Purpose: To present a modified evisceration technique with a full-thickness horizontal sclerotomy and assess post-operative motility and long-term outcomes.
Methods: This is a retrospective chart review of patients who underwent evisceration with a single surgeon (TJM). The standard initial steps of evisceration were performed. Before implant placement, a complete radial sclerotomy was extended posteriorly at the 3 and 9 o'clock positions, 2 mm above the optic nerve, longitudinally dividing the medial and lateral rectus insertions. The scleral halves were mobilized, allowing them to "swing" forward and overlap over the spherical implant. In a subgroup of five patients, postoperative motility was assessed by marking the conjunctiva overlying the implant and taking photos in extreme gazes. Operative and non-operative eye measurements were compared in SiliconCoach Digitizer Software.
Results: Thirty patients were identified (16 male, 14 female; mean age 56.9, range 4.6-90.1 years). Eleven patients were noted to have phthisis bulbi. Implant sizes were 18 mm ( = 13), 20 mm ( = 14), and 22 mm ( = 2) with a mean of 19.24 mm. Mean horizontal and vertical motility ratios of operated to non-operated eye were 0.61 ± 0.18 and 0.76 ± 0.28, respectively, with no statistically significant differences ( = 0.38).
Conclusions: Evisceration with complete horizontal full thickness sclerotomy is an effective technique that prevents the sclera from limiting implant size, even in patients with phthisis bulbi. Longitudinal division of the recti insertions also did not affect function or implant stability.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/01676830.2025.2456496 | DOI Listing |
Diabetol Int
January 2025
Department of Endocrinology and Diabetes, NTT Medical Center Tokyo, 141-86255-9-22 Higashi-Gotanda, Shinagawa-ku, Tokyo Japan.
A 73-year-old Japanese woman was admitted to our hospital with anorexia, weight loss, and fever. A few weeks prior to admission, she became aware of anorexia. She was leukopenic, complement-depleted, and positive for antinuclear antibodies and anti-double stranded DNA antibodies.
View Article and Find Full Text PDFPharmacoecon Open
January 2025
Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Objectives: Immune checkpoint inhibitor (ICI)-containing treatment is currently prescribed as first-line treatment for all patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. However, only 30-45% of patients show no progression within 12 months after treatment start. Various biomarkers are being studied to save costly and potentially harmful treatment in non-responders.
View Article and Find Full Text PDFOrbit
January 2025
Ruiz Department of Ophthalmology and Visual Science, McGovern Medical School at University of Texas Health Science Center, Houston, Texas, USA.
Purpose: To present a modified evisceration technique with a full-thickness horizontal sclerotomy and assess post-operative motility and long-term outcomes.
Methods: This is a retrospective chart review of patients who underwent evisceration with a single surgeon (TJM). The standard initial steps of evisceration were performed.
Front Immunol
January 2025
Laboratory of Molecular Immunology, Institute of Molecular Biology, Slovak Academy of Sciences, Bratislava, Slovakia.
Introduction: Diffuse parenchymal lung diseases (DPLD) cover heterogeneous types of lung disorders. Among many pathological phenotypes, pulmonary fibrosis is the most devastating and represents a characteristic sign of idiopathic pulmonary fibrosis (IPF). Despite a poor prognosis brought by pulmonary fibrosis, there are no specific diagnostic biomarkers for the initial development of this fatal condition.
View Article and Find Full Text PDFInfect Drug Resist
January 2025
Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
We present a rare case of asymptomatic allergic bronchopulmonary aspergillosis (ABPA) concurrent with active pulmonary tuberculosis. Allergic bronchopulmonary aspergillosis is an immunological pulmonary disorder characterized by hypersensitivity to Aspergillus fumigatus, while pulmonary tuberculosis (PTB) is a complex infection caused by Mycobacterium tuberculosis (MTB). The association between pulmonary tuberculosis infections and Aspergillus infections remains a fascinating area of inquiry.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!